Sec Form 4 Filing - PEIZER TERREN S @ BIOVIE INC. - 2018-07-03

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person PEIZER TERREN S 2. Issuer Name and Ticker or Trading Symbol BIOVIE INC. [ BIVI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O ACUITAS GROUP HOLDINGS, LLC, 120 COLORADO AVENUE, #230 3. Date of Earliest Transaction (MM/DD/YY) 07/03/2018 (Street) SANTA MONICA, CA90404 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/13/2018( 1 ) C 1,600,000( 2 ) A 1,600,000( 2 ) I See Footnote( 3 ) Common Stock 01/02/2019 A 1,600( 2 )( 4 ) A $ 0 1,601,600 D Common Stock 06/24/2019( 5 ) A 1,526,334( 2 ) A $ 45 3,127,934 I See Footnote( 3 ) Common Stock 09/24/2019 A 1,125,000( 2 ) A 4,252,934 I See Footnote( 3 ) Common Stock 01/02/2020 A 4,422 A 4,257,356 I See Footnote( 3 ) Common Stock 01/02/2020 A 1,600( 4 ) A $ 0 4,258,956 D Common Stock 09/22/2020 A( 8 ) 5,359,832 A 9,618,788 I See Footnote( 3 ) Common Stock 09/22/2020 M( 8 ) 1,549,750 A $ 0.0001 11,168,538 I See Footnote( 3 ) Common Stock 06/10/2021 A 8,361,308 A 19,529,846 I See Footnote( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Convertible Preferred Stock ( 10 ) 07/03/2018 P 1,600,000( 2 ) ( 10 ) ( 10 ) Common Stock 1,600,000( 2 ) ( 10 ) 1,600,000( 2 ) I See Footnote( 3 ) Warrants (right to buy) $ 2.25 07/03/2018 P 1,713,331( 2 ) 07/03/2018 07/03/2024 Common Stock 1,713,331( 2 ) ( 10 ) 1,713,331( 2 ) I See Footnote( 3 ) Series A Convertible Preferred Stock ( 10 ) 08/03/2018( 1 ) C 1,600,000( 2 ) ( 10 ) ( 10 ) Common Stock 1,600,000( 2 ) ( 10 ) 0 I See Footnote( 3 ) Warrants (right to buy) ( 5 ) 06/24/2019( 5 ) D 1,713,331( 2 ) 07/03/2018 07/03/2024 Common Stock 1,713,331( 2 ) ( 5 ) 0 I See Footnote( 3 ) 10% Convertible Debenture due 2020 ( 6 ) 09/24/2019 A 12/01/2019 09/24/2020 Common Stock ( 6 ) ( 6 ) $ 2,000,000( 6 ) I See Footnote( 3 ) Warrants (right to buy) ( 6 )( 11 ) 09/24/2019 A 1,250,000( 2 ) 11/22/2019 09/24/2024 Common Stock 1,250,000( 2 ) ( 6 ) 1,250,000( 2 ) I See Footnote( 3 ) Warrants (right to buy) ( 6 )( 11 ) 07/13/2020 A 299,750 07/13/2020 07/13/2025 Common Stock 299,750 ( 6 ) 299,750 I See Footnote( 3 ) 10% Convertible Debenture due 2020 ( 12 ) 09/22/2020 D( 12 ) 12/01/2019 09/24/2020 Common Stock ( 6 ) $ 0 0 I See Footnote( 3 ) Warrants (right to buy) ( 11 ) 09/22/2020 M 1,250,000( 2 ) 11/22/2019 09/24/2024 Common Stock 1,250,000( 2 ) ( 8 ) 0 I See Footnote( 3 ) Warrants (right to buy) ( 11 ) 09/22/2020 M 299,750 07/13/2020 07/13/2025 Common Stock 299,750 ( 8 ) 0 I See Footnote( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other PEIZER TERREN S C/O ACUITAS GROUP HOLDINGS, LLC 120 COLORADO AVENUE, #230 SANTA MONICA, CA90404 X X Signatures /s/ Joanne Wendy Kim, Attorney-in-Fact 08/26/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )See Exhibit 99.1 ( 2 )Adjusted to reflect the 125-for-1 reverse stock split effectuated by the Issuer on November 22, 2019 (the "Reverse Stock Split"). ( 3 )Acuitas Group Holdings, LLC ("Acuitas"), is an entity beneficially owned and controlled by Terren S. Peizer. ( 4 )The Issuer granted 1,600 shares of common stock to the reporting person as compensation for his service on the Issuer's board of directors. ( 5 )Pursuant to a letter agreement with the Issuer dated June 24, 2019, Acuitas agreed to modify its existing rights under the 2018 SPA and agreed to immediately exchange the 2018 Warrants such that it effectively exercised its warrant in full pursuant to a cashless exercise thereof at an assumed then-current market price of $45 per share (adjusted to reflect the Reverse Stock Split) and, as a result, received an aggregate of 95% of the shares covered thereby. ( 6 )See Exhibit 99.1 ( 7 )The Issuer paid $13,487 of accrued interest on the Debenture through the issuance of 4,422 shares of the Issuer's common stock to Acuitas. ( 8 )See Exhibit 99.1 ( 9 )The Issuer issued these shares to NeurMedix, Inc. ("NeurMedix") in partial consideration for the acquisition of certain assets from NeurMedix and the assumption of certain liabilities of NeurMedix pursuant to the Asset Purchase Agreement, dated April 27, 2021, by and among the Issuer, NeurMedix, Inc. and Acuitas. In connection with the closing, NeurMedix assigned the rights to receive such shares to Acuitas. ( 10 )See Exhibit 99.1 ( 11 )Exercisable at the lower of $4 (adjusted to reflect the Reverse Stock Split) or 80% of the offering price to the public in the Uplisting Offering. ( 12 )On September 22, 2020, the Issuer paid approximately $1.8 million to Acuitas satisfy all amounts owed on the Debenture due September 24, 2020.

Remarks: Exhibit 99.1 - Explanation of Responses

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.